GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis
pharmaceutical investing GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
